Scheduled vs as-needed firsekibart to prevent gout attacks
Part of Bones, joints & muscles, Kidney & urinary clinical trials.
This study compares taking Firsekibart (a medicine that helps prevent gout attacks) on a fixed schedule versus only when you feel an attack coming on. It is for people who have already been on Firsekibart for 24 weeks without any flares, to see if continuing on a regular schedule is better than taking it "as needed."
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with gout (using standard criteria).
- You have already completed 24 weeks of treatment with Firsekibart (by injection) without having any gout attacks.
- You had at least 2 gout attacks in the year before starting Firsekibart.
- You are willing to follow the study's plan for lowering uric acid, which may include staying on your current medication or starting a new one.
- You have not used steroids, colchicine, or NSAIDs (like ibuprofen) for gout in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, ABP-745, for people having an acute gout flare. It aims to see if the drug is safe and helps reduce pain and inflammation.
This trial tests an experimental tablet (SHR4640) added to the standard gout medicine febuxostat (40 mg daily) for people whose uric acid remains too high despite febuxostat alone. The goal is to see if the combination lowers uric acid more effectively and safely.
This study tests a new medicine called IBI3011 to see if it can reduce pain and inflammation during an acute gout flare. It's for people whose current gout flare treatments haven't worked well or caused side effects.
This study tests whether a potassium citrate tablet can help people with gout lower uric acid and prevent flares. It is for adults on stable gout medication who are not having a current flare.
This trial tests a new medicine called Firsekibart for people who have frequent gout attacks. It aims to see if the medicine can reduce the chance of another attack over 24 weeks.
This study looks at whether people with gout whose uric acid is well controlled and whose joints are clear on ultrasound can safely stop their daily uric acid-lowering medication. Participants are randomly assigned to either continue their current medication or stop it, and their health is monitored to see if stopping leads to gout flares or joint damage.
Hear when a new Gout Flares trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.